CliffBio
small molecule

ANORO ELLIPTA

UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE

Loss of exclusivityNovember 2030latest FDA-listed patent expiry
CompanyGLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND

Drug detail

Brand nameANORO ELLIPTA
Active ingredientUMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE
StrengthEQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH
Dosage formPOWDER
RouteINHALATION
ModalitySmall molecule
FDA approvalDecember 2013
Marketing statusRX

Listed patents

PatentExpiresType
11090294November 2030use U-3203
9750726November 2030product
12396986November 2030product
7488827December 2027substance, product
8511304*PEDDecember 2027—
8511304June 2027product

More from GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ANORO ELLIPTA patent cliff — loss of exclusivity November 2030 | CliffBio